HighTower Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

HighTower Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,488	Closed	-$12K	–	3667
2022 Q1	$12K	Buy	2,488 +1,422	+133%	+$8.94K	﹤0.01%	3206
2021 Q4	$6K	Buy	1,066 +300	+39%	+$2.55K	﹤0.01%	3195
2021 Q3	$8K	Buy	766 +6	+0.8%	+$75	﹤0.01%	3045
2021 Q2	$13K	Sell	760 -334	-31%	-$6.33K	﹤0.01%	2985
2021 Q1	$29K	Buy	1,094 +334	+44%	+$15.2K	﹤0.01%	2877
2020 Q4	$27K	Buy	+760	New	+$27.5K	﹤0.01%	2462

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HighTower Advisors's EVFM Position: Q2 2022 in Review

HighTower Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 2,488 shares — an estimated $12K sold.

HighTower Advisors first reported a position in EVFM in Q4 2020 and held it in 6 quarters. The position peaked at $29K in Q1 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

HighTower Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
HighTower Advisors sold 2,488 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $12K.
HighTower Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
HighTower Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $29K in Q1 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.